OPKO Health Inc.

Regulatory Filings • Jun 2, 2020

FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients����� ����� �� ����� �FDA������ ����� �RAYALDEE����� ����� false

����� ���', ����	2 380
OPKO HEALTH, INC
Corporation no: 2279206	10802
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	01/06/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-049453	Time of broadcast: 22:42 22:37:58

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onFDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients ����� ����� �� ����� � FDA ������ ����� � RAYALDEE ����� ������

20200601PRSigned.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ GSM	Date of revision of form structure: 22/04/2020
Address: Ashlegan 16 , Kiryat Gat 8211804   Israel , Tel: 08-9300051 , Fax: 08-9300091
E-mail address: yphilip@opko.com   Company site: Www.Opko.Com
Previous names of reporting entity:
Name of the Signatory: Philip Yifat Position of Signatory in the reporting corporation: General Counsel Name of Employer Company:
Address: Golda Meir 7 , Nes Ziona 7414002 Telephone: 08-9300051 Facsimile: 08-9300091 E-mail: yphilip@opko.com 1